Elicio Therapeutics, Inc. (ELTX) Investor Relations Documents

Elicio Therapeutics, Inc. (ELTX) investor relations documents from the company's IR site: 5 presentations, 14 press releases; latest deck 2026-01-11. Read in-app with summaries. First-party data.

Corporate Presentation: Elicio Therapeutics is a clinical-stage biotech developing lymph node-targeted cancer immunotherapies, with ELI-002 7P Phase 2 data expected in 1H 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseElicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-10Press releaseElicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancr
2026-07-06Press releaseElicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
2026-07-02Press releaseElicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-06-29Press releaseElicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-17Press releaseElicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoin
2026-06-15Press releaseElicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for
2026-06-01Press releaseElicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immu
2026-05-11Press releaseElicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-04-16Press releaseElicio Therapeutics Reports Inducement Grants
2026-03-17Press releaseElicio Therapeutics Reports Inducement Grants
2026-03-12Press releaseElicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-02-18Press releaseElicio Therapeutics Reports Inducement Grants
2026-01-16Press releaseElicio Therapeutics Reports Inducement Grants
2026-01-11PresentationCorporate Presentation
2025-10-30PresentationAMPLIFY-7P Phase 2: T cell responses induced by lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma
2025-09-17PresentationAMPLIFY-7P Phase 2 Immunogenicity Data
PresentationAMPLIFY-7P Phase 1a: Lymph node-targeted amphiphile therapeutic cancer vaccine in patients with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
PresentationAMPLIFY-7P, a first in human safety and efficacy trial of adjuvant mKRAS-specific lymph node-targeted Amphiphile ELI-002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)

ELTX overview · ELTX earnings · ELTX financials · ELTX KPIs · ELTX ownership · ELTX peers · ELTX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.